Rheolytic thrombectomy with Angiojet in thrombus‐containing lesions

The AngioJet thrombectomy device removes thrombus by creating a negative pressure and causing fragmentation of the thrombus. The objective was to study the safety and efficacy of this thrombectomy device during coronary interventions and to report the results of our experience. We studied 72 patients (mean age, 64.9 ± 12.6 years; 79% males) who had an AngioJet procedure during coronary intervention; 33 (46%) had vein graft intervention. All patients had angiographic thrombus. Most patients presented either with unstable angina (54%) or acute myocardial infarction (32%) within 24 hr. The procedural success was high with AngioJet (93%). TIMI grade 3 flow was achieved in 79% of lesions treated with AngioJet. In‐hospital mortality was 1.4%, death/Q‐wave myocardial infarction was 4.2%, and the composite endpoint of death and Q‐wave myocardial infarction/revascularization was 5.6% for patients undergoing AngioJet. Subgroup analysis of patients with vein graft intervention demonstrated high procedural success in those undergoing AngioJet (91%). At 1‐year follow‐up of the successful percutaneous interventions with AngioJet, the mortality, death/Q‐myocardial infarction, and composite endpoint rates were 10%, 13.3%, and 35.5%, respectively. Long‐term event‐free survival was worse in vein graft interventions. The incidence of death, death/myocardial infarction, or composite endpoints at 1 year was 16%, 19%, and 46%, respectively. High procedural success can be achieved with the AngioJet thrombectomy device in lesions containing thrombus. It is effective in both native coronary arteries and vein graft interventions. However, the long‐term outcome of patients with vein graft intervention was worse. Cathet Cardiovasc Intervent 2002;56:1–7. © 2002 Wiley‐Liss, Inc.

[1]  M. Leon,et al.  Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting. , 2000, Journal of the American College of Cardiology.

[2]  G. Stone,et al.  Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. , 2000, The New England journal of medicine.

[3]  Bruce R. Brodie,et al.  Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction , 1999 .

[4]  S. Snapinn,et al.  Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and s , 1999, Circulation.

[5]  D. Holmes,et al.  The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. , 1999, Journal of the American College of Cardiology.

[6]  Wilson Gj,et al.  Preclinical evaluation of a rheolytic catheter for percutaneous coronary artery/saphenous vein graft thrombectomy. , 1999 .

[7]  C. Di Mario,et al.  Prevention of distal embolization during saphenous vein graft lesion angioplasty. Experience with a new temporary occlusion and aspiration system. , 1999, Circulation.

[8]  M. Nobuyoshi,et al.  Thrombectomy with AngioJet catheter in native coronary arteries for patients with acute or recent myocardial infarction. , 1999, The American journal of cardiology.

[9]  J E Morris,et al.  Preclinical evaluation of a rheolytic catheter for percutaneous coronary artery/saphenous vein graft thrombectomy. , 1999, The Journal of invasive cardiology.

[10]  David P Miller,et al.  Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Block , 1998, Journal of the American College of Cardiology.

[11]  R. Califf,et al.  Does Intracoronary Thrombus Influence the Outcome of High Risk Percutaneous Transluminal Coronary Angioplasty? Clinical and Angiographic Outcomes in a Large Multicenter Trial fn1fn1This study was suppported by a grant from Centocor, Inc. , 1998 .

[12]  R. Califf,et al.  Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. , 1998, Journal of the American College of Cardiology.

[13]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[14]  Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II , 1997, The Lancet.

[15]  M. Bell,et al.  Influence of procedural success on immediate and long-term clinical outcome of patients undergoing percutaneous revascularization of occluded coronary artery bypass vein grafts. , 1996, Journal of the American College of Cardiology.

[16]  P. Teirstein,et al.  Angioscopic versus angiographic detection of thrombus during coronary interventional procedures. , 1995, The American journal of cardiology.

[17]  D. Holmes,et al.  Intracoronary thrombus: still a risk factor for PTCA failure? , 1995, Catheterization and cardiovascular diagnosis.

[18]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[19]  B. Rutherford,et al.  Initial and long-term outcome of 83 patients after balloon angioplasty of totally occluded bypass grafts. , 1994, Journal of the American College of Cardiology.

[20]  D. Faxon,et al.  Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1990, Circulation.

[21]  S. Ellis,et al.  Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. , 1988, Circulation.

[22]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[23]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.